Breaking Down ABA Chemicals Corporation Financial Health: Key Insights for Investors

Investors peering into ABA Chemicals Corporation (300261.SZ) will find a mixed financial picture: the company posted quarter-ending June 30, 2025 revenue of 346.01 million CNY (down 6.29% sequentially) while trailing twelve-month revenue rose to 1.27 billion CNY (+25.51% YoY) after 2024 annual sales of 1.20 billion CNY (-6.00%); profitability remains under pressure with a 2024 net loss of 257.70 million CNY and a TTM net profit margin of -21.44%, operational strains evident in a latest-quarter operating margin of -4.05% and TTM EPS of -0.22, balance-sheet metrics showing total assets around 4.09-4.15 billion CNY against liabilities near 1.70-2.01 billion CNY and a debt-to-equity ratio of 63.4%, liquidity anchored by total cash of 257.15 million CNY and positive quarterly net cash change of 100.74 million CNY, and market valuation signaling investor expectations with market caps reported at 6.49 billion CNY (Dec 22, 2025) and 6.91 billion CNY (Jul 1, 2025), a trailing P/E of 58.60, forward P/E of 29.88, P/S near 5.3 and P/B of 3.47-data points that frame the risks (negative margins, -10.37% ROE, -2.45% ROA) alongside growth levers like seven production bases, three R&D centers, ~12% North American specialty-chemical market share and strategic partnerships in sustainable chemicals that could shape future performance.

ABA Chemicals Corporation (300261.SZ) - Revenue Analysis

• Quarter (ended 2025-06-30) revenue: 346.01 million CNY (down 6.29% vs prior quarter).
• Trailing twelve months (TTM) revenue as of 2025-06-30: 1.27 billion CNY (up 25.51% YoY).
• Full-year 2024 revenue: 1.20 billion CNY (down 6.00% YoY).
• Revenue per share (latest quarter): 7.98 CNY.
• Market capitalization (2025-12-22): 6.49 billion CNY; Price-to-Sales (P/S): 5.29.

• Short-term dynamics: sequential quarterly decline (-6.29%) suggests near-term revenue softness or seasonality requiring monitoring of backlog and order intake.
• Medium-term trend: TTM growth of 25.51% YoY indicates recovery and expansion following the 2024 revenue contraction (-6.00%).
• Valuation context: P/S of 5.29 implies the market prices future growth expectations into the current revenue base; compare with peers for relative attractiveness.
• Per-share metric: 7.98 CNY revenue per share provides a basis for per-share valuation multiples and sensitivity analysis versus EPS and cash flow.

ABA Chemicals Corporation (300261.SZ) - Profitability Metrics

• 2024 net loss: -257.70 million CNY, a 213.1% increase in losses vs. 2023.
• TTM net profit margin: -21.44% - continued negative profitability on sales.
• Latest quarter operating margin: -4.05% - operating activities are loss-making.
• ROA (TTM): -2.45% - assets generate negative returns.
• ROE (TTM): -10.37% - equity holders face negative returns.
• EPS (TTM): -0.22 CNY per share - negative earnings per share.

• Implications for investors:
  • Capital erosion risk given persistent losses and negative ROE.
  • Margin recovery required to restore profitability - monitor operating margin trends.
  • EPS and net margin trends important for valuation and dilution/financing risks.

ABA Chemicals Corporation (300261.SZ) - Debt vs. Equity Structure

Key balance-sheet metrics for ABA Chemicals show a moderate leverage profile with some reported variances in asset and liability totals across disclosures. The available figures indicate a debt-to-equity ratio around 63.4%, total debt of 1.35 billion CNY, and shareholders' equity near 2.13 billion CNY. The interest coverage ratio is not available, limiting assessment of interest-servicing capacity.

• Total assets reported: 4.09 billion CNY (latest quarter) and 4.15 billion CNY (alternate figure).
• Total liabilities reported: 1.70 billion CNY (latest quarter) and 2.01 billion CNY (alternate figure).
• Total debt: 1.35 billion CNY.
• Total shareholder equity: 2.13 billion CNY.
• Debt-to-equity ratio: 63.4% (reported).
• Interest coverage ratio: Not available / not disclosed.

Implications for investors and areas for follow-up:

• Leverage level (63.4% debt-to-equity) suggests moderate reliance on debt financing versus equity.
• Absolute debt (1.35 billion CNY) relative to assets (~4.1 billion CNY) implies debt comprises roughly one-third of total assets.
• Missing interest coverage ratio requires checking income statement disclosure for operating profit and finance costs to assess interest-servicing ability.
• Reconciling the differing asset/liability figures (4.09 vs. 4.15 billion assets; 1.70 vs. 2.01 billion liabilities) with company filings or interim notes is advisable.
• Review liquidity and maturity profile of the 1.35 billion CNY debt to understand refinance or short-term repayment risks.

For additional investor-context and shareholder composition that may affect capital structure considerations, see: Exploring ABA Chemicals Corporation Investor Profile: Who's Buying and Why?

ABA Chemicals Corporation (300261.SZ) - Liquidity and Solvency

Key balance-sheet and cash-flow figures for the latest quarter show available cash, leverage and capital structure dynamics that investors should weigh.

• Total cash: 257.15 million CNY
• Net change in cash (quarter): +100.74 million CNY
• Total liabilities: 1.70 billion CNY
• Total assets: 4.09 billion CNY
• Total shareholder equity: 2.13 billion CNY
• Interest coverage ratio: not available

• The positive net change in cash (+100.74M CNY) improves near-term liquidity flexibility.
• A debt-to-assets ratio of ~41.6% and debt-to-equity of ~79.8% indicate moderate leverage; equity covers a majority of the asset base.
• Cash represents ~6.3% of total assets, a moderate liquid cushion but not a large cash runway versus liabilities (1.70B).
• Lack of an interest coverage ratio requires review of income statement interest expense and EBITDA to judge solvency under stress scenarios.

For broader corporate context, see: ABA Chemicals Corporation: History, Ownership, Mission, How It Works & Makes Money

ABA Chemicals Corporation (300261.SZ) - Valuation Analysis

Key market valuations as of July 1, 2025 provide a snapshot of how investors price ABA Chemicals relative to earnings, sales and book value. These metrics highlight both premium market expectations and sensitivity to future earnings execution.

• Market capitalization: 6.91 billion CNY
• Trailing P/E: 58.60
• Forward P/E: 29.88
• Price-to-Sales (P/S): 5.32
• Price-to-Book (P/B): 3.47
• Enterprise value-to-revenue (EV/Revenue): 6.13

At a glance, the combination of a very high trailing P/E and a materially lower forward P/E implies the market expects meaningful earnings growth or margin expansion over the next 12 months. The P/S and EV/Revenue multiples indicate investors are paying a premium on revenue as well, while the P/B shows the equity is trading several times reported net assets.

Investor implications:

• A high trailing P/E (58.60) signals either historically compressed EPS or a premium for growth; confirm with recent margin and EPS trends.
• The nearly 50% decline from trailing to forward P/E (58.60 → 29.88) suggests projected earnings expansion - validate assumptions behind analyst forecasts.
• P/S of 5.32 and EV/Revenue of 6.13 place valuation above commodity chemical peers; assess competitive positioning, product mix, and pricing power.
• P/B of 3.47 indicates market assigns value to intangibles, tech or niche positions - review balance sheet quality and ROE trends.

For further context on shareholder composition, recent flows and who's buying ABA Chemicals, see: Exploring ABA Chemicals Corporation Investor Profile: Who's Buying and Why?

ABA Chemicals Corporation (300261.SZ) - Risk Factors

Key financial indicators for ABA Chemicals Corporation (300261.SZ) point to material risks that investors should weigh carefully. Below are the principal risk areas grounded in the company's recent profitability, efficiency and leverage metrics.

• Persistent unprofitability: Trailing twelve months (TTM) net profit margin is -21.44%, indicating sustained losses relative to revenue and pressure on retained earnings and cash generation.
• Operational inefficiency: Latest quarter operating margin is -4.05%, signaling the company is not covering operating costs from core business activities in the most recent period.
• Low asset utilization: Return on assets (TTM) is -2.45%, implying assets are generating negative returns and capital employed is not delivering value.
• Weak shareholder returns: Return on equity (TTM) is -10.37%, reflecting negative returns to equity holders and dilution of shareholder value if losses persist.
• Negative per-share earnings: Earnings per share (EPS) (TTM) is -0.22, showing loss on a per-share basis which can pressure equity valuations and dividend sustainability.
• Moderate leverage: Debt-to-equity ratio of 63.4% suggests meaningful indebtedness that can amplify risk during revenue shortfalls or rising interest rates.

Specific investor considerations based on these metrics:

• Liquidity risk: Negative margins and EPS can strain operating cash flow, increasing reliance on external financing or asset sales.
• Refinancing risk: With 63.4% debt-to-equity, the company may face refinancing pressure if credit conditions tighten or interest rates rise.
• Earnings recovery uncertainty: Negative ROA and ROE show management must materially improve asset returns and profitability to restore investor confidence.
• Valuation and dilution risk: Continued losses may lead to equity dilution if the company issues shares to shore up capital, impacting existing shareholders.

For broader context on ownership and investor activity, see: Exploring ABA Chemicals Corporation Investor Profile: Who's Buying and Why?

ABA Chemicals Corporation (300261.SZ) - Growth Opportunities

• Production footprint: 7 production bases enabling scale, regional diversification and logistics advantages.
• R&D capability: 3 dedicated R&D centers focused on new medicines and pesticides, supporting high-margin specialty products and faster product cycle times.
• Market position: Top-five supplier of specialty chemicals in North America with ~12% market share, providing leverage to capture incremental demand.
• Brand & distribution: Established reputation and distribution networks that reduce commercialization time and increase channel reach.
• Sustainability orientation: Ongoing shift toward environmentally friendly alternatives and sustainable development practices that align with regulatory and customer trends.
• Strategic partnerships: Collaborations with renewable energy sector players targeting joint ventures in sustainable chemicals, creating potential new revenue streams.

How these factors translate into tangible growth vectors:

• Product mix upgrade - moving from commodity to specialty chemicals with higher margins due to R&D-driven proprietary formulations.
• Geographic expansion - leveraging North American market share (≈12%) to expand adjacent product lines and capture cross-border demand.
• Sustainable product portfolio - introducing greener chemistries that address regulatory tailwinds and premium pricing opportunities.
• JV-driven scale - monetizing partnerships with renewable energy firms via co-developed products and joint manufacturing.
• Faster commercialization - R&D centers shorten time-to-market for new agrochemical and pharmaceutical intermediates.

• Investor relevance: ABA Chemicals' combination of manufacturing scale (7 bases), R&D depth (3 centers), and a ~12% North American share positions the company to capture both near-term specialty demand and longer-term sustainable-chemicals growth.
• Actionable indicators to monitor: new product approvals from R&D centers, revenue mix shift toward specialty lines, progress of renewable-sector JVs, and North American sales growth vs. competitors.